Introduction
Chronic myelogenous leukemia (CML) is a malignant disorder of the human hematopoietic stem cell characterized by a reciprocal translocation of chromosomes 9 and 22 (t [9;22] [q34:q11]), generating the Ph chromosome in over 90% of patients. 1 At the molecular level the c-abl proto-oncogene is translocated from its normal loocation on chromosome 9 to the breakpoint cluster region (bcr) on chromosome 22, forming a hybrid bcr/abl gene. 2 Animal models have indicated a causal relationship between bcr/abl and initiation and perpetuation of CML-like diseases. 3 Clinically, CML is characterized by a high number of immature hematopoietic progenitor cells of malignant origin in bone marrow and with typical features in the peripheral blood.
The only treatment proven to be curative for CML is allogeneic bone marrow transplantation, which is available for only approximately 35% of patients, because of lack of a suitable donor, advanced age or medical status. 4, 5 Treatment with interferon ␣ (IFN) leads to a return to complete or almost complete Ph-negative hematopoiesis in less than 10-20% of early stage patients. 6 The observation that sufficient numbers of Ph-negative hematopoietic stem cells coexist with their malignant counterparts during early chronic phase (CP) of CML provides the rationale for the development of autologous transplantation protocols. [7] [8] [9] [10] [11] [12] The main problem of autologous transplantation is the substantial contamination of bone marrow and blood with malignant cells. However, several groups reported that the majority of the CD34-positive, HLA-DR low and negative cells are Ph-negative during early chronic phase, 13, 14 while CML progenitor cells coexpress CD34 and HLA-DR. Due to this phenotypic difference between benign and malignant hematopoietic progenitors it is possible to select for the two cell populations. Furthermore, Verfaillie et al 15 reported that the number of viable, benign hematopoietic progenitor cells within the CD34 + DR low subpopulation in bone marrow from early chronic phase CML might be sufficient to reconstitute the hematopoietic compartment following autologous transplantation after high-dose chemotherapy. Different chemotherapy approaches have been used for in vivo reduction of malignant cells. 11 The aim of this study was to obtain Ph-negative PBPC by collecting them during the early phase of hematopoietic recovery after mobilization with idarubicin, cytarabine and etoposide (ICE) chemotherapy followed by simultaneous administration of rhIL-3 and rhG-CSF. The present study demonstrates both the feasibility of mobilizing Ph-negative PBPC during the early phase of hematopoietic recovery after ICE chemotherapy and priming with simultaneous rhIL-3 and rhG-CSF and the further reduction of Ph-chromosome positive cells using in vitro culture, as shown previously for bone marrow.
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Materials and methods
Patient characteristics and transplantation of PBPC PBPC were collected from eight patients, one female and seven males in chronic phase CML, with a median age of 42.5 years (range 25-46). Prior therapy of all patients is shown in Table 1 . Interferon ␣ treatment, if previously given, was stopped at least 2 months before mobilization therapy, and changed to hydroxyurea. All patients gave informed consent before participating in the study according to institutional ethics committee guidelines.
Mobilization was started with administration of polychemotherapy (priming with G-CSF 5 g/kg day 1, idarubicin 8 mg/m 2 days 2-4, cytarabine 400 mg/m 2 days 2-5, and etoposide 150 mg/m 2 days 2-4) followed by simultaneous administration of rhG-CSF (10 g/kg) and rhIL-3 (5 g/kg) day 7 until last leukapheresis. Preparative regimen for autologous transplantation contained busulfan (4 mg/kg b.w., day −7 until day −4) and cyclophosphamide (60 mg/kg b.w. day −3 until day −2). PBPC were transplanted on day 0. Intravenous rhG-CSF administration was started on day +3 and continued until WBC counts of Ͼ1000/ml for 3 consecutive days. 
Leukapheresis and cell selection
Collection of PBPC was started using a CS-3000 Plus Blood Cell Separator (Baxter, Unterschleissheim, Germany) when peripheral blood counts showed leukocytes у 500/l (Coulter Counter, Krefeld, Germany) or CD34-positive cells reached у1% of mononuclear cells (MNC); Ͼ2.5 × 10 6 CD34 + cells/kg was considered as a sufficient graft. In all cases a back-up product was obtained.
Purification of CD34-positive cells from leukapheresis was performed using the Ceprate System (CellPro, Bothell, WA, USA) or Isolex 300 (Baxter, Unterschleissheim, Germany), according to the manufacturer's instruction.
Depletion of HLA-DR-negative cells was carried out by the MaxSep magnetic cell separation system (Baxter) according to the manufacturer's instructions using the murine monoclonal anti-HLA-DR antibody, CLB-HLA-class II (Hiss Diagnostics, Amsterdam, The Netherlands) and as second step antibody sheep anti-mouse IgG coupled to magnetic beads (Dynabeads M-450; Dynal, Hamburg, Germany).
Immunophenotypic analysis of peripheral white blood cells
Differential blood counts were performed at 1:10 dilution using a Coulter counter (Coulter). Mononuclear cells (MNC) were isolated by density gradient centrifugation over FicollHypaque (Pharmacia, Freiburg, Germany), washed twice in Iscove's modified Dulbecco's medium (IMDM) and adjusted to a concentration of 4.5 × 10 6 /ml. Cell staining was performed using the following monoclonal antibodies In vitro culture and colony assays of PBPC Purified CD34-positive cells were grown in RPMI 1640 (Biochrom KG, Berlin, Germany) supplemented with 2% autologous plasma, recombinant human stem cell factor (rh SCF), rhIL-1, rhIL-3, rhIL-6 at a concentration of 100 ng/ml each (all from Genzyme Diagnostics, Cambridge, UK) and erythropoietin at a concentration of 1 U/ml (Cilag, Bad Homburg, Germany). CD34-positive cells were cultured for 14 days in a humidified 5% CO 2 atmosphere. Unseparated MNC as well as culture cells were grown in a standard methylcellulose assay as described previously. 16 
Cytogenetic analysis of bone marrow
Cytogenetic analysis was performed only before mobilization therapy. MNC from bone marrow aspirates were isolated by density gradient centrifugation over Ficoll-Hypaque (Pharmacia). MNC were cultured for 24-72 h in RPMI medium 1640 supplemented with 10% bovine serum albumin in a humidified 5% CO 2 atmosphere. Chromosome preparation was performed in accordance with conventional methods using hypotonic KCl and fixed in acid/alcohol as described. 17 Metaphases were analyzed after GTG banding. Between 14 and 20 metaphases were analyzed for each culture.
Detection of bcr/abl mRNA by RT-PCR Oligonucleotides: Oligonucleotide primers were prepared by using automated synthesis on a Biosearch 8600 DNA synthesizer according to the manufacturer's instruction.
RT-PCR amplification using nested primers was performed as previously described. 18, 19 The CML cell line K562 served as positive control and as negative control the lymphoid Daudi cell line. The housekeeping gene abl was used to detect the intact sample RNA. The sensitivity of the RT-PCR was one bcr/abl-positive cell in 1 × 10 5 -1 × 10 6 normal cells.
Interphase fluorescence in situ hybridization (FISH)
FISH analysis for the bcr/abl fusion gene was performed using probes for the c-abl oncogene and the M-bcr region (Oncor, Gaithersburg, MD, USA) to detect t(9,22)(q34;q11) in interphase cells, after density gradient centrifugation over Ficoll-Hypaque (Pharmacia), according to the manufacturer's instructions. On the day of hybridization, slides were thawed and air-dried at room temperature for 1 h. The hybridization, washing and analysis procedures have been described elsewhere. 20 Interphase nuclei were scored, if both copies of the bcr and abl probes were detectable. For each sample, 100 nuclei were analyzed. Our laboratory's threshold of detection was determined at Ͼ6% to classify any specimen as Ph positive. FISH was used as this method is feasible most of the time, especially when few cells are analyzed as during the mobilisation phase with very low leukocyte counts. Then classic cytogenetics is often unsuccessful. Using FISH as the only method throughout all analyses we were able to compare results between patients.
Results
Ph chromosome and bcr/abl mRNA status before mobilization Cytogenetic analysis was performed in bone marrow aspirates from six patients within 3 days before the start of mobilization therapy ( Table 1 ). The Ph translocation t(9;22) was found in all patients. UPN 2 showed a complex variant t(1;9;22) translocation. A finding of 100% Ph-positive metaphases was detected in five patients; one patient showed 81% Ph-positive metaphases. In addition to metaphase cytogenetics, interphase FISH was used to determine the percentage of Ph-positive cells. As shown in Table 1 all analyzed probes contained more than 6% Ph-positive interphase cells (detection limit) and were therefore classified as Ph-positive (range 9-60%; mean 26.5% Ph-positive). We could show that percentage of Mobilization and cell processing Mobilization of Ͼ2.5 × 10 6 cells/kg b.w., which was considered sufficient for autologous transplantation, was possible in all patients as described elsewhere (manuscript submitted). Four patients mobilized sufficient numbers of CD34-positive cells (mean 25.6 CD34 + kg b.w.; range 5.13-57.8 CD34 + /kg b.w.) with three leukaphereses, two patients needed four, one patient six and one patient seven procedures. All patients showed a continuous increase of their peripheral blood leukocyte count.
Ph chromosome detection and bcr/abl mRNA status during mobilization and after cell processing
The absolute and relative numbers of Ph-positive cells in peripheral blood leukocytes decreased after mobilization chemotherapy (ICE) in all patients and the percentage of Ph-positive cells remained below or around the detection limit for the following 30 days (Figure 1 ). The number of Ph-positive cells during the early phase of hematopoietic recovery after mobilization chemotherapy and simultaneous administration of rhIL-3 and rhG-CSF did not increase while the number of leukocytes increased considerably. Three patients showed a slight increase in their percentage of Ph-positive cells from the first to the last leukapheresis up to a maximum of 10, 22 and 10% (UPN 1, 2 and 7) . In all but one patient the highest percentage of Ph-positive cells was detectable before mobilization and was followed by a constant decrease. Table 2 (Table 1) it was possible by our assay system to detect a significant reduction in the number of Phpositive cells in all patients after mobilization therapy (Table  2) . Surprisingly, patient UPN 7 showed an increase in the percentage of Ph-positive cells after CD34 selection (Tables 1 and  2 ), which was accompanied by positive RT-PCR.
In vitro culture of purified CD34-positive cells and colonies derived from leukapheresis products Cells cultured in vitro were bcr/abl mRNA and Ph chromosome negative as analyzed by RT-PCR and FISH ( Table 2 ). The number of cells recovered after 14 days of in vitro culture ranged from 3 × 10 4 to 9 × 10 4 /ml, an up to three-fold increase. In addition to in vitro culture, single colonies from standard colony assays of unseparated MNC were picked and examined by RT-PCR and FISH. Data are summarized in Table  3 . A total of 77 colonies were analyzed by RT-PCR: three colony-forming unit granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM); 23 burst-forming unit erythroid (BFU-E); 51 colony-forming unit cells (CFU-C). Only three colonies out of 77 were detected to be bcr/abl mRNA positive. This correlates well with our data from FISH analyses of cells from leukapheresis products. Ten colonies analyzed by FISH as well as RT-PCR were below the detection limits of FISH and PCR (Table 3 ).
Figure 1
Percentage of Ph chromosome-positive cells and median white blood cell count during mobilization after ICE chemotherapy and simultaneous administration of rhIL-3 and rhG-CSF. The threshold for Ph positivity by FISH was 6% (dotted area).
Content of Ph chromosome-positive cells in peripheral blood analyzed by FISH before and after the first month after PBPC transplantation Data are summarized in Table 4 . Only one patient (UPN 2) was found to be Ph positive by FISH after transplantation, but showed a significant decrease from 60 to 9% in Ph-positive cells compared to the Ph status before mobilization therapy. In all other patients it was possible to reduce the number of Ph-positive cells in peripheral blood below the detection limit of FISH. Additional PCR analyses were all positive for bcr/abl.
Discussion
It has been reported in previous studies that selection of bone marrow cells on the basis of the CD34-positive and HLA-DRnegative phenotype results in recovery of mainly Ph-negative long-term culture-initiating cells (LTC-IC) in chronic phase CML patients. 13, 14 Recently, Verfaillie et al 15 demonstrated that a large-scale selection of bcr/abl mRNA-negative CD34-positive and HLA-DR-negative cells from bone marrow is possible, especially if selection is performed in the early stages of disease. In addition, it has been demonstrated that cells collected by leukapheresis from CML patients during early recovery after chemotherapy-induced aplasia are able to sustain long-term Ph-negative hematopoiesis after autografting. 11, 21 Furthermore, it could be shown that it is feasible to recruit Ph-negative LTC-IC, a very primitive class of clonogenic precursors, into peripheral blood. 21 Our approach to obtain PBPCs for autologous transplantation was based on the combination of collection of PBPC during early recovery after chemotherapy and ex vivo purging of leukapheresis products by immunaffinity column separation (CD34 positive) and magnetic bead separation (HLA-DR depletion). Barnett et al 10 could demonstrate a marked and selective loss of primitive Ph chromosome-positive progenitors after in vitro culture of CML bone marrow. Therefore we tested in vitro culture to reduce the percentage of Ph-positive cells as an additional purging step.
Interphase FISH and RT-PCR were used to analyze the Ph status of different cell populations. We applied both detection methods because recent studies suggested that expression of bcr/abl mRNA might not occur in very primitive cells. 22, 23 Therefore some PCR-negative results could be explained by low bcr/abl expression as well as small numbers of Ph chromosome-positive cells in the analyzed population. 
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IL-3-and G-CSF-mobilized PBSC in early chronic phase CML
Brackets symbolize that the probes were pooled for the next processing (CD34 positive or HLA-DR negative selection).
-, not done.
Although the number of leukocytes increased considerably in all but one patient the relative number of Ph-positive cells did not increase during the early phase of hematopoietic recovery after mobilization chemotherapy and simultaneous administration of rhIL-3 and rhG-CSF (Figure 1) . The combination of rhIL-3 and rhG-CSF was chosen as it was thought that an early acting cytokine might be able to preferentially mobilize rather immature progenitors which might be Ph negative. In addition, in cell culture this combination was shown to maintain LTCICs to a higher degree as other cytokines alone or in combination. 25 Leukapheresis products analyzed by FISH and RT-PCR (Table 2) showed a significant decrease in the percentage of Ph-positive cells in all patients compared to the Ph status in peripheral blood before chemotherapy. In four patients the percentage of Ph-positive cells dropped below the detection limit by FISH. A substantial number of RT-PCR analyses was bcr/abl mRNA negative. In contrast to all other patients UPN 2 and 7 had been treated for 15 and 20 months, respectively, after initial diagnosis. Therefore higher numbers of Ph-positive cells after leukapheresis and CD34 purification in those patients might be a result of more advanced disease. This observation is in accordance with data reported by Carella. 26 It was shown that collection of Ph-negative PBPC after chemotherapy is possible if patients are in early chronic phase CML and without prior therapy while a longer disease duration might result in failure of mobilization of Ph-negative cells. In our study seven out of eight patients obtained prior therapy with a median disease of 11 months. It was possible to reduce the number of Ph chromosome-positive cells measured in peripheral blood before and after PBPCT in all but one patient below the detection limit by FISH (Table 4) . Current efforts are being directed to use high speed fluorescence-activated cell sorting (FACS) for purification of a cell population which is CD34 positive and HLA-DR negative, because enrichment of these cells by the combination of immunaffinity and magnetic bead column separation has proved to be insufficient. Neither the enrichment of CD34-positive cells by immun- 3/9 ---BFU-E, burst-forming unit erythrocyte; CFU-C, colony-forming unit cells; CFU-GEMM, colony-forming unit granulocyte, erythrocyte, monocyte, megakaryocyte. affinity column as first step and subsequent depletion of HLA-DR-negative cells labeled with microbeads nor the reverse order allowed the selection of a highly purified CD34-positive and HLA-DR-negative cell population. Cells examined after 14 days of in vitro culture and all subsequent colonies analyzed by FISH and RT-PCR (UPN 4) or RT-PCR only (UPN 1 and 2) were Ph chromosome negative and bcr/abl mRNA negative. These findings indicate that in vitro culture of PBPCs after ICE chemotherapy and administration of rhIL-3 and rhG-CSF results in a further reduction of malignant cells and might be suitable for eradication of remaining Ph-positive cells. After ex vivo culture Ph-positive cells remained below the detection limit of FISH and previously positive RT-PCR results reverted to negative in all cases. In vitro culture combined with other purging methods such as antisense approaches or addition of cytostatic agents might result in even further reduction of Ph-positive cells. 27 In conclusion, our data demonstrate that it is possible to mobilize substantial numbers of Ph-negative PBPC during early recovery after ICE chemotherapy and simultaneous administration of rhIL-3 and rhG-CSF.
